NeuroBo Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • NeuroBo Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$10.1M, a 165% decline year-over-year.
  • NeuroBo Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$26.5M, a 33.6% decline year-over-year.
  • NeuroBo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$15.9M, a 19.1% increase from 2022.
  • NeuroBo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$19.6M, a 28.3% decline from 2021.
  • NeuroBo Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$15.3M, a 48.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$26.5M -$10.1M -$6.28M -165% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$20.2M -$6.88M -$4.36M -173% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$15.9M -$5.67M +$4.76M +45.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$20.6M -$3.89M -$789K -25.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$19.9M -$3.81M -$587K -18.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$19.3M -$2.52M +$355K +12.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$19.6M -$10.4M -$5.85M -128% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$13.8M -$3.1M +$360K +10.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$14.1M -$3.22M +$707K +18% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$14.8M -$2.88M +$455K +13.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$15.3M -$4.58M +$14.9M +76.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$30.2M -$3.46M -$404K -13.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$29.8M -$3.93M -$1.53M -64.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$28.3M -$3.33M +$1.42M +29.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$29.7M -$19.5M -$7.32M -60.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$22.4M -$3.06M +$585K +16% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$23M -$2.39M -$505K -26.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$22.5M -$4.75M -$2.3M -93.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$20.2M -$12.2M -$8.89M -269% Oct 1, 2019 Dec 31, 2019 10-K 2021-04-15
Q3 2019 -$11.3M -$3.65M +$2.26M +38.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$13.5M -$1.89M +$4.65M +71.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$18.2M -$2.45M +$4.61M +65.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-20
Q4 2018 -$22.8M -$3.3M +$3.27M +49.7% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-18
Q3 2018 -$26.1M -$5.91M +$2.63M +30.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$28.7M -$6.53M +$3.98M +37.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$32.7M -$7.06M +$439K +5.85% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$33.1M -$6.57M +$661K +9.15% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 -$33.8M -$8.54M -$5.14M -151% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-18
Q2 2017 -$28.6M -$10.5M -$8.68M -471% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-18
Q1 2017 -$20M -$7.5M -$5.28M -237% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-18
Q4 2016 -$14.7M -$7.23M -$4.72M -188% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-20
Q3 2016 -$9.98M -$3.4M -$1.04M -43.8% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-20
Q2 2016 -$8.94M -$1.84M -$230K -14.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-20
Q1 2016 -$8.71M -$2.23M -$637K -40.1% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-20
Q4 2015 -$8.08M -$2.51M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-21
Q3 2015 -$2.37M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-21
Q2 2015 -$1.61M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-21
Q1 2015 -$1.59M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.